Casi Pharmaceuticals Stock Performance

CASI Stock  USD 0.24  0.03  14.29%   
The firm shows a Beta (market volatility) of 0.42, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, CASI Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding CASI Pharmaceuticals is expected to be smaller as well. At this point, CASI Pharmaceuticals has a negative expected return of -1.18%. Please make sure to confirm CASI Pharmaceuticals' skewness, as well as the relationship between the rate of daily change and price action indicator , to decide if CASI Pharmaceuticals performance from the past will be repeated in the future.

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days CASI Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in March 2026. The recent confusion may also be a sign of long-lasting up-swing for the firm traders. ...more
Last Split Factor
1:10
Last Split Date
2022-06-02
1
CASI Pharmaceuticals Announces Up to 20 Million Convertible Note Financing
12/11/2025
2
CASI Academy Launches Sustainable Investing Program for Hong Kongs MPF Industry
12/18/2025
3
CASI Pharmaceuticals wins Nasdaq extension to meet listing rules
12/23/2025
4
CASI Pharmaceuticals issues US5M 12 percent convertible note as first tranche - Stock Titan
12/30/2025
5
CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia - ACCESS Newsw...
01/12/2026
6
CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejecti...
01/15/2026
7
CASI Pharmaceuticals Inc. Short Interest Down 24.1 percent in January
02/03/2026
8
12 Health Care Stocks Moving In Fridays Intraday Session - Benzinga
02/13/2026
9
CASI Pharmaceuticals Closes Third Tranche of US20 Million Convertible Note Financing - TipRanks
02/20/2026
Begin Period Cash Flow17.1 M
Total Cashflows From Investing Activities11.2 M

CASI Pharmaceuticals Relative Risk vs. Return Landscape

If you would invest  99.00  in CASI Pharmaceuticals on November 30, 2025 and sell it today you would lose (75.00) from holding CASI Pharmaceuticals or give up 75.76% of portfolio value over 90 days. CASI Pharmaceuticals is currently does not generate positive expected returns and assumes 11.0738% risk (volatility on return distribution) over the 90 days horizon. In different words, 99% of stocks are less volatile than CASI, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days CASI Pharmaceuticals is expected to under-perform the market. In addition to that, the company is 14.6 times more volatile than its market benchmark. It trades about -0.11 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.08 per unit of volatility.

CASI Pharmaceuticals Target Price Odds to finish over Current Price

The tendency of CASI Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 0.24 90 days 0.24 
close to 99
Based on a normal probability distribution, the odds of CASI Pharmaceuticals to move above the current price in 90 days from now is close to 99 (This CASI Pharmaceuticals probability density function shows the probability of CASI Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days CASI Pharmaceuticals has a beta of 0.42 suggesting as returns on the market go up, CASI Pharmaceuticals average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding CASI Pharmaceuticals will be expected to be much smaller as well. Additionally CASI Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   CASI Pharmaceuticals Price Density   
       Price  

Predictive Modules for CASI Pharmaceuticals

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as CASI Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of CASI Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.010.2311.30
Details
Intrinsic
Valuation
LowRealHigh
0.061.1812.25
Details
Naive
Forecast
LowNextHigh
00.1911.26
Details
1 Analysts
Consensus
LowTargetHigh
3.644.004.44
Details

CASI Pharmaceuticals Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. CASI Pharmaceuticals is not an exception. The market had few large corrections towards the CASI Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold CASI Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of CASI Pharmaceuticals within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-1.4
β
Beta against Dow Jones0.42
σ
Overall volatility
0.17
Ir
Information ratio -0.13

CASI Pharmaceuticals Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of CASI Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for CASI Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
CASI Pharmaceuticals generated a negative expected return over the last 90 days
CASI Pharmaceuticals has high historical volatility and very poor performance
CASI Pharmaceuticals has some characteristics of a very speculative penny stock
CASI Pharmaceuticals has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 28.54 M. Net Loss for the year was (39.26 M) with profit before overhead, payroll, taxes, and interest of 9.61 M.
CASI Pharmaceuticals currently holds about 24.57 M in cash with (29.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.81, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
CASI Pharmaceuticals has a frail financial position based on the latest SEC disclosures
Roughly 87.0% of the company shares are held by company insiders
Latest headline from news.google.com: CASI Pharmaceuticals Closes Third Tranche of US20 Million Convertible Note Financing - TipRanks

CASI Pharmaceuticals Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of CASI Stock often depends not only on the future outlook of the current and potential CASI Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. CASI Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding15.3 M
Cash And Short Term Investments16.1 M

CASI Pharmaceuticals Fundamentals Growth

CASI Stock prices reflect investors' perceptions of the future prospects and financial health of CASI Pharmaceuticals, and CASI Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CASI Stock performance.

About CASI Pharmaceuticals Performance

By evaluating CASI Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into CASI Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if CASI Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if CASI Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 99.21  144.18 
Return On Tangible Assets(0.66)(0.69)
Return On Capital Employed(2.07)(1.97)
Return On Assets(0.66)(0.69)
Return On Equity(19.09)(18.13)

Things to note about CASI Pharmaceuticals performance evaluation

Checking the ongoing alerts about CASI Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for CASI Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
CASI Pharmaceuticals generated a negative expected return over the last 90 days
CASI Pharmaceuticals has high historical volatility and very poor performance
CASI Pharmaceuticals has some characteristics of a very speculative penny stock
CASI Pharmaceuticals has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 28.54 M. Net Loss for the year was (39.26 M) with profit before overhead, payroll, taxes, and interest of 9.61 M.
CASI Pharmaceuticals currently holds about 24.57 M in cash with (29.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.81, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
CASI Pharmaceuticals has a frail financial position based on the latest SEC disclosures
Roughly 87.0% of the company shares are held by company insiders
Latest headline from news.google.com: CASI Pharmaceuticals Closes Third Tranche of US20 Million Convertible Note Financing - TipRanks
Evaluating CASI Pharmaceuticals' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate CASI Pharmaceuticals' stock performance include:
  • Analyzing CASI Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CASI Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
  • Examining CASI Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating CASI Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of CASI Pharmaceuticals' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of CASI Pharmaceuticals' stock. These opinions can provide insight into CASI Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating CASI Pharmaceuticals' stock performance is not an exact science, and many factors can impact CASI Pharmaceuticals' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for CASI Stock analysis

When running CASI Pharmaceuticals' price analysis, check to measure CASI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CASI Pharmaceuticals is operating at the current time. Most of CASI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of CASI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CASI Pharmaceuticals' price. Additionally, you may evaluate how the addition of CASI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Transaction History
View history of all your transactions and understand their impact on performance
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency